Original Articles
Prognostic factors affecting remissions based on minimal residual disease (MRD) examination in paediatric acute lymphoblastic leukaemia patients after induction phase treatment
Authors:
Ni Nyoman Anik Cindi Yuliastini ,
Medical School of Udayana University, Sanglah Hospital, Denpasar, Bali, ID
About Ni
Department of Paediatrics
Ketut Ariawati Ariawati,
Medical School of Udayana University, Sanglah Hospital, Denpasar, Bali, ID
About Ketut Ariawati
Department of Paediatrics
I. Made Gede Dwi Lingga Utama,
Medical School of Udayana University, Sanglah Hospital, Denpasar, Bali, ID
About I.
Department of Paediatrics
I. Gusti Ngurah Sanjaya Putra,
Medical School of Udayana University, Sanglah Hospital, Denpasar, Bali, ID
About I.
Department of Paediatrics
Ni Putu Veny Kartika Yantie,
Medical School of Udayana University, Sanglah Hospital, Denpasar, Bali, ID
About Ni
Department of Paediatrics
Made Sukmawat
Medical School of Udayana University, Sanglah Hospital, Denpasar, Bali, ID
About Made
Department of Paediatrics
Abstract
Introduction: Acute lymphoblastic leukaemia (ALL) is the most common cancer in children. Remission in the induction phase plays an important role in the prognosis of ALL. Minimal residual disease (MRD) examination can detect cancer cell residues that cannot be detected by conventional morphological examination methods.
Objectives: To identify prognostic factors affecting ALL remissions at the end of the induction phase of chemotherapy treatment using MRD examination as the paediatric gold standard.
Method: This is a retrospective cohort study. Forty-six children diagnosed with ALL aged 1 to 18 years in the paediatric ward of Sanglah General Hospital, Bali, Indonesia were enrolled in this study from 2017 to 2019. Data with categorical variables were analysed using the Chi-Square test. A p-value <0.05 was considered statistically significant.
Results: A total of 46 subjects, aged 1 to 10 years, was included in this study. Twenty-five (54.3%) patients experienced relapse, 21 (45.7%) of them achieving remission by MRD examination at the end of the induction phase. Bivariate test results showed a significant difference in therapeutic response based on L1 type (p = 0.028) and platelet levels (p = 0.017). Multivariate test results showed a platelet level >30,000/ cu mm caused remission in ALL patients (CI 95% 1.486-28.326, p=0.013). The L1 type was significantly associated with treatment response (95% CI 0.013-0.617, p = 0.014).
Conclusions: Platelet levels >30.000/cu mm and L1 type of leukaemia are prognostic factors for remissions based on the examination of MRD in paediatric patients with ALL after the induction phase.
Sri Lanka Journal of Child Health, 2023; 52(1): 27-32
How to Cite:
Yuliastini, N.N.A.C., Ariawati, K.A., Utama, I.M.G.D.L., Putra, I.G.N.S., Yantie, N.P.V.K. and Sukmawat, M., 2023. Prognostic factors affecting remissions based on minimal residual disease (MRD) examination in paediatric acute lymphoblastic leukaemia patients after induction phase treatment. Sri Lanka Journal of Child Health, 52(1), pp.27–32. DOI: http://doi.org/10.4038/sljch.v52i1.10469
Published on
05 Mar 2023.
Peer Reviewed
Downloads
